Charu Aggarwal, MD

Articles

Strategic Approaches to Biomarker Testing in NSCLC: Optimal Timing

November 17th 2023

Experts reflect on the evolving landscape of biomarker testing in lung cancer, examining its crucial role in treatment decisions and advancements in perioperative and adjuvant therapies.

Advancement in NSCLC Precision Medicine: Biomarker Testing

November 17th 2023

Explore the latest breakthroughs in precision medicine with a focus on biomarker testing and emerging targets in patients with non–small cell lung cancer.

Dr. Aggarwal on Treating Patients With EGFR Mutations in NSCLC

December 15th 2022

Charu Aggarwal, MD, MPH, discusses treating patients with EGFR-mutant non­–small cell lung cancer.

Latest in Lung, Genitourinary, Gynecologic, and Breast Cancers From ASCO 2022: Drs Charu Aggarwal, Bradley McGregor, Robert Coleman, and Kevin Kalinsky

June 7th 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Dr. Aggarwal on NGS in Molecular Testing in NSCLC

April 5th 2022

Charu Aggarwal, MD, MPH, discusses the optimal use of next-generation sequencing in molecular testing in non­–small cell lung cancer.

Dr. Aggarwal the Significance of the IMpower010 Trial in PD-L1+ NSCLC

December 15th 2021

Charu Aggarwal, MD, MPH, discusses the significance of the phase 3 IMpower010 trial in patients with PD-L1–positive non–small cell lung cancer.

Next Steps in Managing Chemo-Induced Myelosuppression

September 16th 2021

Trials of interest exploring various novel therapies as chemoprotection in patients with solid tumor cancers.

Expanded Access to Trilaciclib for Patients With ES-SCLC

September 16th 2021

Jared Weiss, MD, reacts to new measures that increase patient access and provider reimbursement to trilaciclib for patients with extensive-stage small cell lung cancer.

Limitations When Managing Chemo-Induced Myelosuppression

September 2nd 2021

Pros and cons of strategies used to manage chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer.

Clinical Impact of Chemo-Induced Myelosuppression in ES-SCLC

August 26th 2021

Drs Charu Aggarwal and Jared Weiss react to the impact that chemotherapy-induced myelosuppression can have on patients with extensive-stage small cell lung cancer, as well as the overall health system.

Chemo-Induced Myelosuppression in ES-SCLC

August 26th 2021

Types of chemotherapy-induced myelosuppression that typically occur in patients with extensive-stage small cell lung cancer and considerations for treating patients based on risk factors and presentation of adverse events.

Dr. Aggarwal on Investigational Biomarkers in Lung Cancer

October 16th 2020

Charu Aggarwal, MD, MPH, discusses investigational biomarkers in lung cancer.

Dr. Aggarwal on Emerging Treatment Approaches in ALK+ NSCLC

July 23rd 2020

Charu Aggarwal, MD, MPH, discusses emerging treatment approaches in ALK-positive non–small cell lung cancer.

Dr. Aggarwal on Triplet Therapy in EGFR-Mutant Lung Cancer

July 27th 2018

Charu Aggarwal, MD, assistant professor of Medicine, University of Pennsylvania, discusses triplet therapy in EGFR-mutant lung cancer.

Moving Forward in Head and Neck Squamous Cell Cancer

January 25th 2018

Development of effective therapies for metastatic head and neck cancer has been challenging, and progress has been slow.